A unique financing solution for healthtech startups

WiSEED, a Leading Crowdfunding Player in France, and Quest for Health, France’s Premier Health Start-up Accelerator, Announce a Partnership to Offer Financing Solutions for Health Start-ups

Among the financing options is an innovative convertible bridge bond, a first in the biotech, medtech, and digital health sectors.

Building on the success of the WiClub Santé, an innovative financing tool that supported seven start-ups over two years, the two organizations are combining their expertise to provide new investment opportunities. Their partnership enables investors to support several high-potential French health start-ups through two types of financial instruments:

1. Convertible Bridge Bonds

A novel financing solution offering an interest rate above 10% with a duration of 12 to 16 months. This investment, which carries the same risks as equity investments in the event of conversion, is accessible starting at €100. It provides start-ups with temporary liquidity during pivotal moments, such as entering clinical phases or scaling commercial development.

2. Equity Investments

A traditional option allowing investors to take equity stakes in candidate start-ups while enjoying tax benefits through defiscalization or contribution-transfer mechanisms.

This initiative addresses a pressing need among French health start-ups seeking funding to reach their next financing round, enabling milestones such as clinical trials.

Current Campaigns for Quest for Health-Supported Start-ups on the WiSEED Platform:

• BiPer Therapeutics
  Focused on developing first-in-class drug candidates targeting tumor survival mechanisms to treat cancer patients. Its lead program, BP001, addresses gastrointestinal cancers.
  Fundraising closed on November 10, raising €488,000.
• Dianosic
  Developer of the only resorbable intranasal insert with drug elution capabilities to treat chronic rhinitis and sinusitis, as well as schizophrenia and Parkinson’s disease.
  Current fundraising target: €600,000, with an 11% interest rate and a 12-month exit horizon.

Mathilde Iclanzan, CEO of WiSEED:
“We are delighted to offer our investors the opportunity to benefit from Quest for Health’s expertise in supporting start-ups while promoting this new category of financial instruments, which enable participation in medical innovation.”

Guillaume Vetter-Genoud, Director of Quest for Health:
“This tool addresses a key need expressed by health start-ups in France and internationally. It aims to accelerate their development ahead of their next funding round or commercial breakthrough, while offering investors a unique opportunity to fund start-ups before they reach a major valuation inflection point.”

To access the WiSEED platform: https://www.wiseed.com/

Disclaimer

Investing in shares or convertible bonds in unlisted companies involves risks, including the total or partial loss of capital, illiquidity risks, and the risk of non-payment of interest.